Entry Point Capital, LLC Macrogenics Inc Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 2,695 shares of MGNX stock, worth $14,148. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,695Holding current value
$14,148% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding MGNX
# of Institutions
169Shares Held
62.5MCall Options Held
819KPut Options Held
79.4K-
Bellevue Group Ag Kuesnacht, V89.97MShares$52.3 Million2.3% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.15MShares$32.3 Million1.09% of portfolio
-
Black Rock Inc. New York, NY5.7MShares$29.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.68MShares$19.3 Million0.0% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $323M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...